Anabolic profiles in late‐stage cancer patients responsive to hydrazine sulfate

References and notes

• Gold , J . 1968 . “Proposed Treatment of Cancer by Inhibition of Gluconeogenesis” . Oncology , 22 : 185 – 207 .
   PubMed Web of Science ®Google Scholar
• Gold , J . 1974 . “Cancer Cachexia and Gluconeogenesis” . Ann NY Acad Sci , 230 : 103 – 110 .
   PubMed Web of Science ®Google Scholar
• Gold , J . 1979 . “Hydrazine Sulfate and Cancer Cachexia” . Nutr Cancer , 1 (4) : 4 – 9 .
   Google Scholar
• Gold , J . 1980 . “Preservation of the Nutritional Integrity of the Cancer Patient: Reversal of Cancer Cachexia by Hydrazine Sulfate” . Cancer Detection and Prevention , 3 (1) : 75
   Google Scholar
• Danova , LA , Gershanovich , ML , Filov , VA , Kondratyev , VB and Evin , VA . 1977 . “Study of Side Effects of Hydrazine Sulfate” . In Problems in Radiobiology and Biological Action of Cytostatic Compounds , Edited by: Goldberg , ED . 192 – 193 . Tomsk, , USSR : Tomsk Institute of Medicine .
   Google Scholar
• Danova , LA , Kondratyev , VB , Gershanovich , ML and Filov , VA . 1977 . “Results of Administration of Hydrazine Sulfate to Patients With Hodgkins Disease” . Therap Arch: Probl Hematol , 29 (8) : 45 – 47 .
   Google Scholar
• Gershanovich , ML , Danova , LA , Kondratyev , VB , Malyugina , LL , Studkov , AN , Seits , JF and Filov , VA . 1976 . “Clinical Data on the Antitumor Activity of Hydrazine Sulfate” . Cancer Treat Rep , 60 : 933 – 935 .
   PubMedGoogle Scholar
• Gershanovich , ML and Filov , VA . 1979 . “Hydrazine Sulfate in Late‐Stage Cancer: Completion of Initial Clinical Trials in 225 Evaluable Patients” . Proc Am Assoc Cancer Res , 20 : 240
   Google Scholar
• Gold , J . 1975 . “Use of Hydrazine Sulfate in Terminal and Preterminal Cancer Patients: Results of Investigational New Drug (IND) Study in 84 Evaluable Patients” . Oncology , 32 : 1 – 10 .
   PubMed Web of Science ®Google Scholar
• Seits , JF , Gershanovich , ML , Filov , VA , Danova , LA , Kondratyev , VB , Malyugina , LL , Muller , NR , Polina , RI , Rudakov , VG and Stukov , AN . 1975 . “Experimental and Clinical Data on the Antitumor Action of Hydrazine Sulfate” . Vopr Onkol , 21 (1) : 45 – 52 .
   PubMedGoogle Scholar
• Creagan , ET , Moertel , CG , O'Fallon , JR , Schutt , AJ , O'Connell , MJ , Rubin , J and Frytak , S . 1979 . “Failure of High Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients With Advanced Cancer” . N Engl J Med , 301 : 687 – 690 .
   PubMed Web of Science ®Google Scholar
• Bulovskaya , LN . 1976 . “Acetylation Reaction in Normal and Tumour Bearing Mice” . Vopr Onkol , 22 : 94 – 95 .
   Google Scholar
• Gold , J . 1975 . “Enhancement by Hydrazine Sulfate of Antitumor Effectiveness of Cytoxan, Mitomycin‐C, Methotrexate and Bleomycin, in Walker 256 Carcinosarcoma in Rats” . Oncology , 31 : 44 – 53 .
   PubMedGoogle Scholar
• Gold , J . 1978 . “Potentiation by Clofibrate of in vivo Tumor Inhibition by Hydrazine Sulfate and Cytotoxic Agents, in Walker 256 Carcinosarcoma” . Cancer Biochem Biophys , 3 : 41 – 45 .
   PubMedGoogle Scholar
• Tretyakov , AV and Filov , VA . 1977 . “The Mechanism of Potentiation by Hydrazine Sulfate of the Action of Antitumoral Compounds” . Vopr Onkol , 23 (5) : 94 – 98 .
   Google Scholar
• Request reprints from Dr. Joseph Gold, Director, Syracuse Cancer Research Institute, 600 E. Genesee St., Syracuse, NY 13202.
   Google Scholar